Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486796 | 0.80 | POLB (0.45) | CA12CA9CYP1A2POLBHPGD | |
| SCHEMBL3126212 | 0.79 | KMT2A (0.49) | CA12CA9KMT2AMEN1CYP1A2 | |
| SCHEMBL2855957 | 0.79 | KMT2A (0.49) | CA12CA9KMT2AMEN1CYP1A2 | |
| SCHEMBL3126205 | 0.79 | KMT2A (0.49) | CA12CA9KMT2AMEN1CYP1A2 | |
| SCHEMBL28700642 | 0.77 | CYP1A2 (0.42) | CA12CA9KMT2AMEN1CYP1A2 | |
| SCHEMBL3225070 | 0.77 | KMT2A (0.50) | CA12CA9KMT2AMEN1CYP1A2 | |
| SCHEMBL7469312 | 0.76 | NPC1 (0.49) | CA12CA9KMT2AMEN1NPC1 | |
| SCHEMBL8797866 | 0.76 | NPC1 (0.49) | CA12CA9KMT2AMEN1NPC1 | |
| SCHEMBL8797872 | 0.76 | NPC1 (0.49) | CA12CA9KMT2AMEN1NPC1 | |
| SCHEMBL8769240 | 0.76 | OR51E2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660040-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025006976-A2 | MRNA DISPLAY LIBRARIES AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-3666792-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240294596-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024151615-A1 | MRNA DISPLAY LIBRARIES AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024112880-A1 | B7-H3 TARGETING LIGANDS AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4210729-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4204442-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3660041-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022055877-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022046739-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022046747-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-108064173-A | Partial insulin receptor agonists | 默沙东公司 | 2018-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | CA12 2643/4885CA9 2134/4885KMT2A 2387/4885 |
| US-20240294596-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CA12 4655/4885CA9 4721/4885KMT2A 4174/4885 |
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CA12 4655/4885CA9 4721/4885KMT2A 4174/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CA12 4655/4885CA9 4721/4885KMT2A 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.